Ribosomal protein L6 pseudogene 26 (RPL6P26)

RPL6P26 is a processed pseudogene derived from the ribosomal protein L6 (RPL6) gene, appearing as a dispersed, non-protein coding segment in the human genome[1][5][8]. Like other ribosomal protein pseudogenes, it arose by retrotransposition, resulting in many such copies distributed randomly throughout the genome proportional to chromosome size[5][7]. Pseudogenes like RPL6P26 generally lack functional capacity due to disruptions such as frameshifts or premature stop codons, and do not contribute to cellular processes or disease. Their presence is mainly of genomic interest, serving as evolutionary "snapshots" and genomic markers for studying retrotransposon activity and the evolution of ribosomal proteins[5][7]. RPL6P26 should not be confused with the protein-coding RPL6 gene or its protein product (60S ribosomal protein L6), which is involved in protein synthesis and has functional disease relationships[4][10][9]. RPL6P26 is a pseudogene, not a receptor, transporter, enzyme, or protein[1][12][8]. It is not a therapeutic target, and there is no evidence it participates in any biological process or disease[1][5][7]. There is no evidence or literature supporting roles as a biomarker or drug target, nor associated safety concerns. Any association with protein function or disease concerns applies to the parent gene/protein (RPL6), not the pseudogene RPL6P26[4][10][13]. If a search for functional roles, disease association, biomarkers, or therapeutic targeting is needed, reference should be made to ribosomal protein L6 (RPL6) and not RPL6P26.

Other names

RPL6_9_1550RPL6P26